Reduced Expression Of Scube2 Predicts Poor Prognosis In Gastric Cancer Patients

Signal peptide-CUB-EGF (epidermal growth factor) domain-containing protein 2 (SCUBE2) is a secreted cell-surface glycoprotein. Decreased SCUBE2 expression has been reported in a variety of human cancers, including breast cancer, but its role in gastric cancer (GC) is still unknown. The present study was designed to evaluate the role of SCUBE2 expression in the prognosis of GC patients. SCUBE2 expression in GC tissues was detected by quantitative real-time reverse transcription polymerase chain reaction, Western blotting, and immunohistochemistry. The association between SCUBE2 expression and clinicopathological characteristics was evaluated using the Chi-square test. The Kaplan-Meier method and Cox proportional hazards models were applied to estimate the effect of SCUBE2 expression on survival. Our results show that expression of SCUBE2 in GC tissues is significantly lower than that in adjacent normal gastric mucosa tissues. Loss of SCUBE2 expression was associated with larger tumors (P = 0.001), advanced clinical stage (P = 0.001), T3 or T4 lesion (P = 0.017), lymph node metastasis (P = 0.033), higher histological grade (P = 0.041), and vascular invasion (P = 0.002). Patients with decreased SCUBE2 expression showed poorer recurrence free survival (RFS) and overall survival (OS) than those with higher SCUBE2 expression levels. Furthermore, multivariate analysis indicated that reduced expression of SCUBE2 was an independent prognostic factor predicting poor RFS (HR = 1.764, P = 0.029) and OS (HR = 1.811, P = 0.026). Therefore, expression of SCUBE2 in GC tends to be downregulated, and may serve an important role in predicting the prognosis of GC patients.